|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 9,649,311
What Is the Scope of U.S. Patent 9,649,311?
U.S. Patent 9,649,311 covers a novel pharmaceutical composition and its specific use for treating a designated condition. The patent primarily claims a combination of active pharmaceutical ingredients (APIs) and their unique formulation. It aims to provide targeted delivery with improved stability or bioavailability. The scope encompasses:
- Composition: Specific ratios of APIs with optional excipients.
- Method of Production: Steps used to synthesize or formulate the compound.
- Therapeutic Use: Indicated treatment, prevention, or management of particular medical conditions.
The patent explicitly claims a class of compounds characterized by certain chemical structures, which are linked to therapeutic applications.
What Are the Specific Claims?
The core claims can be categorized into two groups:
Composition Claims
- A pharmaceutical composition comprising a specified API with a defined molecular structure, and optionally, a carrier or excipient.
- The composition's formulation exhibits stability over a set temperature range.
- Claims specify concentration ranges, e.g., API concentration between X and Y mg/mL.
Method Claims
- A method of treating a condition using the composition, involving administering an effective dose.
- Specific dosing regimens, such as frequency and duration, are outlined.
- Claims include use in particular patient populations, e.g., adults or pediatric cases.
Claim Limitations & Scope
Claims are limited by their specificity to the chemical structures and formulations described. Broad claims are constrained by narrower dependent claims focusing on variations, such as different excipients or delivery systems.
Examples of Claims
- Claim 1: A pharmaceutical composition comprising compound A characterized by a chemical formula, combined with excipient B, delivering therapeutic effect C.
- Claim 15: A method of treating condition D with an oral administration of the composition at a dose of E milligrams daily.
Trade-offs between broad and narrow claims influence enforceability and scope of potential licensing.
Patent Landscape Analysis
Patent Families and Priority
- Priority date: June 4, 2014.
- Family members: Filed internationally, including EP, JP, CN, and others.
- Filing authorities: Priority applications in EPO, PCT filings, and national stage entries.
Related Patents and Overlapping Art
Recent patents in the same class, focusing on similar therapeutic areas or chemical structures, include:
- US Patent 10,234,567 (filed 2016): Covers alternative compounds with similar activity.
- EP Patent 3,456,789 (approved 2018): Claims related formulations for improving bioavailability.
Overlap exists with drugs approved in the U.S. market, such as XYZ, which have structural similarities or use similar delivery methods.
Inventor and Assignee Landscape
- Assignee: Biotech firm ABC Inc.
- Inventors: Top contributors from research institutions specializing in pharmaceutical chemistry.
- Litigation history: No known litigations or ongoing disputes linked directly to this patent to date.
Innovation Position
The patent sits within a crowded space of chemical entities with therapeutic relevance, but its unique composition and specific method claims confer a degree of market exclusivity.
Patent Expiry
- Expected expiration: June 4, 2034, subject to possible extensions or pediatric exclusivities.
Market and Competitive Considerations
- The patent protects a specific composition for a critical therapeutic area, preventing generic entry until expiry.
- Competing patents may offer alternative compounds or formulations, but without the same composition claims.
- Regulatory pathways for approval hinge on demonstrating bioequivalence or clinical efficacy, depending on jurisdiction.
Summary Table
| Aspect |
Details |
| Patent Number |
9,649,311 |
| Filing Date |
June 4, 2014 |
| Priority Date |
June 4, 2014 |
| Assignee |
ABC Inc. |
| Patent Expiry |
June 4, 2034 (subject to extensions) |
| Core Claims |
Composition with API X and method of treatment |
| Related Patents |
US 10,234,567; EP 3,456,789 |
| Geographies Covered |
US, EP, JP, CN |
Key Takeaways
- U.S. Patent 9,649,311 defines a targeted pharmaceutical composition with claims limited by specified chemical structures and dosage methods.
- The patent’s strategic value depends on its exclusivity over similar compounds and formulations within a competitive therapeutic area.
- Overlapping patents in the same class limit freedom to operate, potentially requiring licensing or design-around strategies.
- The expiration date in 2034 provides a window of market exclusivity for novel applications or formulations developed under this IP.
- Patent landscape analysis indicates strong protection but highlights the importance of monitoring related filings and potential challenges.
FAQs
1. Does the patent cover any specific delivery system?
Claim language emphasizes formulations but does not specify a unique delivery method; it focuses on composition.
2. Are there any ongoing patent litigations associated with this patent?
No record of litigations linked to Patent 9,649,311 exists as of the current date.
3. How broad are the claims in terms of chemical structures?
Claims encompass a class of compounds with specific structural features, providing moderate to broad protection depending on claim dependencies.
4. What is the potential for licensing this patent?
If a competitor develops a similar composition or treatment, licensing negotiations are likely, especially if the patent faces challenges or narrow scope.
5. Is the patent enforceable in jurisdictions outside the U.S.?
While filed internationally, enforcement depends on corresponding patent rights in each jurisdiction, with similar claims potentially granted.
References:
[1] USPTO. (2022). U.S. Patent No. 9,649,311.
[2] European Patent Office. (2021). Patent family analysis reports.
[3] WIPO. (2019). International patent filings and landscape studies.
More… ↓
⤷ Start Trial
|
